{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:02:59Z","timestamp":1782975779614,"version":"3.54.5"},"reference-count":103,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.drudis.2024.104065","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T23:30:33Z","timestamp":1718753433000},"page":"104065","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inhaled heparin: Past, present, and future"],"prefix":"10.1016","volume":"29","author":[{"given":"Zhewei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binjie","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2024.104065_b0005","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0166-3542(87)90018-0","article-title":"Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro","volume":"7","author":"Ito","year":"1987","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2024.104065_b0010","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1164\/ajrccm.153.6.8665036","article-title":"Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma","volume":"153","author":"Diamant","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.drudis.2024.104065_b0015","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jth.14817","article-title":"Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy","volume":"18","author":"Tang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2024.104065_b0020","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.06.017","article-title":"Cytokine storms: understanding COVID-19","volume":"53","author":"Mangalmurti","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2024.104065_b0025","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cell.2020.09.033","article-title":"SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2","volume":"183","author":"Clausen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2024.104065_b0030","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/0140-6736(92)92064-M","article-title":"Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin","volume":"339","author":"Green","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2024.104065_b0035","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jconrel.2006.04.008","article-title":"The quest for non-invasive delivery of bioactive macromolecules: a focus on heparins","volume":"113","author":"Motlekar","year":"2006","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2024.104065_b0040","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1016\/j.jacc.2016.02.073","article-title":"Heparin-induced thrombocytopenia: a comprehensive clinical review","volume":"67","author":"Salter","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.drudis.2024.104065_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.121457","article-title":"The future of dry powder inhaled therapy: promising or discouraging for systemic disorders?","volume":"614","author":"Ye","year":"2022","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2024.104065_b0050","series-title":"Pharmaceutical Inhalation Aerosol Technology","first-page":"455","article-title":"Dry powder inhalation","author":"de Boer","year":"2019"},{"key":"10.1016\/j.drudis.2024.104065_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2021.118784","article-title":"Polysaccharide-based formulations as potential carriers for pulmonary delivery\u2013a review of their properties and fates","volume":"277","author":"Valente","year":"2022","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.drudis.2024.104065_b0060","doi-asserted-by":"crossref","first-page":"9577","DOI":"10.1021\/acsami.5b12347","article-title":"Antitumor and antimetastasis activities of heparin-based micelle served as both carrier and drug","volume":"8","author":"Mei","year":"2016","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2024.104065_b0065","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/med.20217","article-title":"Recent advances in search of oral heparin therapeutics","volume":"32","author":"Paliwal","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/j.drudis.2024.104065_b0070","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/jamp.2015.1273","article-title":"Inhaled heparin: therapeutic efficacy and recent formulations","volume":"30","author":"Yildiz-Pekoz","year":"2017","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.drudis.2024.104065_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5582\/ddt.8.1","article-title":"Pharmacological effects and clinical applications of ultra low molecular weight heparins","volume":"8","author":"Liu","year":"2014","journal-title":"Drug Discov Ther"},{"key":"10.1016\/j.drudis.2024.104065_b0080","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1016\/j.apsb.2022.01.019","article-title":"Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants","volume":"12","author":"Tu","year":"2022","journal-title":"Acta Pharm Sin b"},{"key":"10.1016\/j.drudis.2024.104065_b0085","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1476-5381.2011.01578.x","article-title":"New anticoagulants - promising and failed developments: new anticoagulants","volume":"165","author":"Harenberg","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.drudis.2024.104065_b0090","series-title":"Properties, uses and side effects","author":"Piyathilake","year":"2012"},{"key":"10.1016\/j.drudis.2024.104065_b0095","doi-asserted-by":"crossref","first-page":"117232","DOI":"10.1016\/j.carbpol.2020.117232","article-title":"Comprehensive landscape of heparin therapy for COVID-19","volume":"254","author":"Shi","year":"2021","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.drudis.2024.104065_b0100","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/jbm.b.34295","article-title":"Rapid endothelialization and controlled smooth muscle regeneration by electrospun heparin-loaded polycaprolactone\/gelatin hybrid vascular grafts","volume":"107","author":"Shi","year":"2019","journal-title":"J Biomed Mater Res B Appl Biomater"},{"key":"10.1016\/j.drudis.2024.104065_b0105","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1172\/JCI116234","article-title":"Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells. Role of Ca2+ mobilization and protein kinase C activation","volume":"91","author":"Taubman","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2024.104065_b0110","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jtho.2020.02.010","article-title":"Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer","volume":"15","author":"Tian","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.drudis.2024.104065_b0115","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.573044","article-title":"Heparin therapy improving hypoxia in COVID-19 patients\u2013a case series","volume":"11","author":"Negri","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.drudis.2024.104065_b0120","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.thromres.2017.10.012","article-title":"Exploring the impact of route of administration on medication acceptance in hospitalized patients: implications for venous thromboembolism prevention","volume":"160","author":"Popoola","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.drudis.2024.104065_b0125","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1073\/pnas.85.16.6132","article-title":"Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro","volume":"85","author":"Baba","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2024.104065_b0130","doi-asserted-by":"crossref","first-page":"13221","DOI":"10.1128\/JVI.02078-14","article-title":"Human coronavirus NL63 utilizes heparan sulfate proteoglycans for attachment to target cells","volume":"88","author":"Milewska","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2024.104065_b0135","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.antiviral.2019.05.004","article-title":"Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545","volume":"168","author":"Modhiran","year":"2019","journal-title":"Antiviral Res"},{"key":"10.1016\/j.drudis.2024.104065_b0140","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/infdis\/jiy081","article-title":"The role of heparan sulfate proteoglycans as an attachment factor for rabies virus entry and infection","volume":"217","author":"Sasaki","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.drudis.2024.104065_b0145","doi-asserted-by":"crossref","first-page":"e00432","DOI":"10.1128\/JVI.00432-17","article-title":"Genome-wide screening uncovers the significance of N-sulfation of heparan sulfate as a host cell factor for chikungunya virus infection","volume":"91","author":"Tanaka","year":"2017","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2024.104065_b0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-018-1045-0","article-title":"Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells","volume":"15","author":"Tamhankar","year":"2018","journal-title":"Virol J"},{"key":"10.1016\/j.drudis.2024.104065_b0155","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.virol.2019.01.019","article-title":"Role of heparan sulfate in the Zika virus entry, replication, and cell death","volume":"529","author":"Gao","year":"2019","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2024.104065_b0160","doi-asserted-by":"crossref","first-page":"12090","DOI":"10.1128\/JVI.78.21.12090-12095.2004","article-title":"DC-SIGN and DC-SIGNR interact with the glycoprotein of marburg virus and the S protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"Marzi","year":"2004","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2024.104065_b0165","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/003655201753265091","article-title":"Low molecular weight heparin treatment in steroid refractory ulcerative colitis: clinical outcome and influence on mucosal capillary thrombi","volume":"36","author":"Vrij","year":"2001","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.drudis.2024.104065_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-020-03240-7","article-title":"Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey","volume":"24","author":"Tzotzos","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.drudis.2024.104065_b0175","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1001\/jamainternmed.2020.3313","article-title":"Is a \u201ccytokine storm\u201d relevant to COVID-19?","volume":"180","author":"Sinha","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.drudis.2024.104065_b0180","article-title":"The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab man be the key to reduce the mortality","volume":"55","author":"Chi","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.drudis.2024.104065_b0185","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/jmv.25770","article-title":"Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19","volume":"92","author":"Gao","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.drudis.2024.104065_b0190","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1160\/TH16-08-0620","article-title":"More than an anticoagulant: do heparins have direct anti-inflammatory effects?","volume":"117","author":"Poterucha","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.drudis.2024.104065_b0195","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10557-021-07251-6","article-title":"Low molecular weight heparin, anti-inflammatory\/immunoregulatory and antiviral effects, a short update","volume":"37","author":"Vitiello","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.drudis.2024.104065_b0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12950-020-0238-7","article-title":"Different signaling pathways involved in the anti-inflammatory effects of unfractionated heparin on lipopolysaccharide-stimulated human endothelial cells","volume":"17","author":"Li","year":"2020","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.drudis.2024.104065_b0205","doi-asserted-by":"crossref","first-page":"959","DOI":"10.2217\/imt-2016-0020","article-title":"Immunotherapeutic implications of IL-6 blockade for cytokine storm","volume":"8","author":"Tanaka","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1016\/j.drudis.2024.104065_b0210","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1160\/TH17-05-0347","article-title":"Nebulized heparin attenuates pulmonary coagulopathy and inflammation through alveolar macrophages in a rat model of acute lung injury","volume":"117","author":"Chimenti","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.drudis.2024.104065_b0215","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.coph.2009.04.008","article-title":"Anti-inflammatory and pro-inflammatory roles of TGF-\u03b2, IL-10, and IL-22 in immunity and autoimmunity","volume":"9","author":"Sanjabi","year":"2009","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.drudis.2024.104065_b0220","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0002-9343(97)89484-3","article-title":"Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis","volume":"100","author":"Siragusa","year":"1996","journal-title":"Am J Med"},{"key":"10.1016\/j.drudis.2024.104065_b0225","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1073\/pnas.061615598","article-title":"Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis","volume":"98","author":"Borsig","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2024.104065_b0230","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1189\/jlb.1203659","article-title":"Heparin-disaccharide affects T cells: inhibition of NF-\u03baB activation, cell migration, and modulation of intracellular signaling","volume":"75","author":"Hecht","year":"2004","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.drudis.2024.104065_b0235","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1021\/bc8003809","article-title":"Heparin\u2212paclitaxel conjugates as drug delivery system: synthesis, self-assembly property, drug release, and antitumor activity","volume":"20","author":"Wang","year":"2009","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.drudis.2024.104065_b0240","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijbiomac.2018.01.195","article-title":"Development of low molecular weight heparin based nanoparticles for metastatic breast cancer therapy","volume":"112","author":"Sun","year":"2018","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2024.104065_b0245","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1076029606291422","article-title":"Recent findings for anti-metastatic potential of heparin","volume":"12","author":"Altundag","year":"2006","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.drudis.2024.104065_b0250","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.thromres.2018.02.144","article-title":"Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): a systematic review and meta-analysis","volume":"173","author":"Li","year":"2019","journal-title":"Thromb Res"},{"key":"10.1016\/j.drudis.2024.104065_b0255","series-title":"Heparin, properties, uses and side effects","first-page":"159","article-title":"Heparin-related nanomaterials","author":"Gu","year":"2012"},{"key":"10.1016\/j.drudis.2024.104065_b0260","first-page":"1229","article-title":"Preventing breast cancer metastasis-heparins as inhibitors of chemokine function","volume":"65","author":"Harvey","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2024.104065_b0265","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2014.02.010","article-title":"The potential of heparanase as a therapeutic target in cancer","volume":"89","author":"Pisano","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.drudis.2024.104065_b0270","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3004","article-title":"Contribution of platelets to tumour metastasis","volume":"11","author":"Gay","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.drudis.2024.104065_b0275","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijpharm.2017.02.051","article-title":"Gambogic acid grafted low molecular weight heparin micelles for targeted treatment in a hepatocellular carcinoma model with an enhanced anti-angiogenesis effect","volume":"522","author":"Yan","year":"2017","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2024.104065_b0280","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12325-019-01124-z","article-title":"Safety and efficacy of enoxaparin in pregnancy: a systematic review and meta-analysis","volume":"37","author":"Jacobson","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.drudis.2024.104065_b0285","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2008.02921.x","article-title":"Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study","volume":"6","author":"Pomp","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.drudis.2024.104065_b0290","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/0002-9378(65)90518-1","article-title":"Placental transport of heparin","volume":"93","author":"Flessa","year":"1965","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.drudis.2024.104065_b0295","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood-2005-02-0626","article-title":"Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy","volume":"106","author":"Greer","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2024.104065_b0300","doi-asserted-by":"crossref","first-page":"844S","DOI":"10.1378\/chest.08-0761","article-title":"Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines","volume":"133","author":"Bates","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2024.104065_b0305","doi-asserted-by":"crossref","first-page":"e691S","DOI":"10.1378\/chest.11-2300","article-title":"VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Bates","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2024.104065_b0310","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S1701-2163(15)30569-7","article-title":"VTE in Pregnancy Guideline Working Group. Venous thromboembolism and antithrombotic therapy in pregnancy","volume":"36","author":"Chan","year":"2014","journal-title":"J Obstet Gynaecol Can"},{"key":"10.1016\/j.drudis.2024.104065_b0315","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejogrb.2012.05.010","article-title":"Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study","volume":"163","author":"Galambosi","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.drudis.2024.104065_b0320","doi-asserted-by":"crossref","first-page":"5184","DOI":"10.1182\/bloodadvances.2020002963","article-title":"Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses","volume":"4","author":"Morgan","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.drudis.2024.104065_b0325","doi-asserted-by":"crossref","first-page":"423","DOI":"10.15585\/mmwr.mm6818e1","article-title":"Vital signs: pregnancy-related deaths, United States, 2011\u20132015, and strategies for prevention, 13 states, 2013\u20132017","volume":"68","author":"Petersen","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.drudis.2024.104065_b0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0020-7292(00)00202-2","article-title":"Low-molecular-weight heparin for thrombophilia in pregnant women","volume":"69","author":"Bar","year":"2000","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.drudis.2024.104065_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12959-019-0213-9","article-title":"Low molecular weight heparins use in pregnancy: a practice survey from Greece and a review of the literature","volume":"17","author":"Papadakis","year":"2019","journal-title":"Thromb J"},{"key":"10.1016\/j.drudis.2024.104065_b0340","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ehj.2003.10.027","article-title":"Percutaneous coronary intervention in diabetic patients with non-ST-segment elevation acute coronary syndromes","volume":"25","author":"Roffi","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.drudis.2024.104065_b0345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2004.01.021","article-title":"Drug-eluting stents: results, promises and problems","volume":"99","author":"Van der Hoeven","year":"2005","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.drudis.2024.104065_b0350","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0169-409X(02)00181-3","article-title":"ATTEMPTS: a heparin\/protamine-based triggered release system for the delivery of enzyme drugs without associated side-effects","volume":"55","author":"Park","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2024.104065_b0355","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/js9502736","article-title":"Accelerated stability studies of heparin","volume":"85","author":"Jandik","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2024.104065_b0360","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/path.1554","article-title":"Heparanase expression during normal liver development and following partial hepatectomy","volume":"203","author":"Goldshmidt","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.drudis.2024.104065_b0365","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/oxfordjournals.jbchem.a022756","article-title":"Purification and characterization of a novel heparinase from Bacteroides stercoris HJ-15","volume":"128","author":"Kim","year":"2000","journal-title":"J Biochem"},{"key":"10.1016\/j.drudis.2024.104065_b0370","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","article-title":"Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications","volume":"56","author":"Labiris","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.drudis.2024.104065_b0375","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1023\/B:PHAM.0000048191.69098.d6","article-title":"Pulmonary delivery of low molecular weight heparins","volume":"21","author":"Yang","year":"2004","journal-title":"Pharm Res"},{"key":"10.1016\/j.drudis.2024.104065_b0380","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199307083290204","article-title":"Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin","volume":"329","author":"Ahmed","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2024.104065_b0385","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1183\/09031936.01.17100360","article-title":"Nebulized heparin in Burkholderia cepacia colonized adult cystic fibrosis patients","volume":"17","author":"Ledson","year":"2001","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2024.104065_b0390","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1089\/jam.2007.0579","article-title":"Facemask design, facial deposition, and delivered dose of nebulized aerosols","volume":"20","author":"Smaldone","year":"2007","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.drudis.2024.104065_b0395","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1089\/jamp.2009.0786","article-title":"Mode of breathing\u2014tidal or slow and deep\u2014through the I-neb Adaptive Aerosol Delivery (AAD) system affects lung deposition of 99mTc-DTPA","volume":"23","author":"Nikander","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.drudis.2024.104065_b0400","doi-asserted-by":"crossref","first-page":"R145","DOI":"10.1186\/cc8040","article-title":"Nebulized antithrombin limits bacterial outgrowth and lung injury in Streptococcus pneumoniae pneumonia in rats","volume":"13","author":"Hofstra","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.drudis.2024.104065_b0405","doi-asserted-by":"crossref","first-page":"R180","DOI":"10.1186\/cc9286","article-title":"Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial","volume":"14","author":"Dixon","year":"2010","journal-title":"Crit Care"},{"key":"10.1016\/j.drudis.2024.104065_b0410","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-2600(20)30470-7","article-title":"Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial","volume":"9","author":"Dixon","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.drudis.2024.104065_b0415","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1186\/s13054-020-03148-2","article-title":"Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence","volume":"24","author":"Van Haren","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.drudis.2024.104065_b0420","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1365-2214.2006.00669.x","article-title":"Microbial contamination of nebulizers in the home treatment of cystic fibrosis","volume":"33","author":"Blau","year":"2007","journal-title":"Child Care Health Dev"},{"key":"10.1016\/j.drudis.2024.104065_b0425","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/ppul.22546","article-title":"Managing treatment complexity in cystic fibrosis: challenges and opportunities","volume":"47","author":"Sawicki","year":"2012","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.drudis.2024.104065_b0430","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1183\/09031936.00090314","article-title":"Inhaled antibiotics: dry or wet?","volume":"44","author":"Tiddens","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2024.104065_b0435","first-page":"131","article-title":"Inhalation drug delivery devices: technology update","volume":"8","author":"Ibrahim","year":"2015","journal-title":"Med Devices (Auckl)"},{"key":"10.1016\/j.drudis.2024.104065_b0440","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1378\/chest.118.4.1069","article-title":"Targeting aerosol deposition in patients with cystic fibrosis: effects of alterations in particle size and inspiratory flow rate","volume":"118","author":"Laube","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.drudis.2024.104065_b0445","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.3390\/pharmaceutics13091455","article-title":"Dry powder inhalers in the digitalization era: current status and future perspectives","volume":"13","author":"Xiroudaki","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104065_b0450","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.addr.2020.05.003","article-title":"Post-inhalation cough with therapeutic aerosols: formulation considerations","volume":"165","author":"Sahakijpijarn","year":"2020","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.drudis.2024.104065_b0455","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1002\/jps.21362","article-title":"Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy","volume":"97","author":"Shur","year":"2008","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2024.104065_b0460","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1089\/jamp.2009.0745","article-title":"Inhalable lactose-based dry powder formulations of low molecular weight heparin","volume":"23","author":"Bai","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.drudis.2024.104065_b0465","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/hc0202.101988","article-title":"In vitro and in vivo evaluation of oral heparin\u2013loaded polymeric nanoparticles in rabbits","volume":"105","author":"Jiao","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2024.104065_b0470","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1002\/jps.22160","article-title":"Inhalable liposomes of low molecular weight heparin for the treatment of venous thromboembolism","volume":"99","author":"Bai","year":"2010","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2024.104065_b0475","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2005.03.018","article-title":"Tricaprylin microemulsion for oral delivery of low molecular weight heparin conjugates","volume":"105","author":"Kim","year":"2005","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2024.104065_b0480","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/md13031133","article-title":"Chitin and chitosan preparation from marine sources. Structure, properties and applications","volume":"13","author":"Younes","year":"2015","journal-title":"Mar Drugs"},{"key":"10.1016\/j.drudis.2024.104065_b0485","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/10717544.2017.1333172","article-title":"Toxicity of orally inhaled drug formulations at the alveolar barrier: parameters for initial biological screening","volume":"24","author":"Fr\u00f6hlich","year":"2017","journal-title":"Drug Deliv"},{"key":"10.1016\/j.drudis.2024.104065_b0490","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1016\/j.ijbiomac.2019.11.190","article-title":"Development of chitosan-coated liposome for pulmonary delivery of N-acetylcysteine","volume":"156","author":"Hamedinasab","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2024.104065_b0495","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/pharmaceutics11010021","article-title":"Microencapsulation and nanoencapsulation using supercritical fluid (SCF) techniques","volume":"11","author":"Soh","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2024.104065_b0500","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1021\/acs.molpharmaceut.7b00967","article-title":"Polysaccharide submicrocarrier for improved pulmonary delivery of poorly soluble anti-infective ciprofloxacin: preparation, characterization, and influence of size on cellular uptake","volume":"15","author":"Ho","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2024.104065_b0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2017.05.016","article-title":"Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis","volume":"51","author":"Vardakas","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.drudis.2024.104065_b0510","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00608-2020","article-title":"Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a post hoc analysis of the AIR-BX studies","volume":"56","author":"Crichton","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.drudis.2024.104065_b0515","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2017.07.015","article-title":"Inhalation delivery of complex drugs\u2014the next steps","volume":"36","author":"de Kruijf","year":"2017","journal-title":"Curr Opin Pharmacol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644624001909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T17:12:22Z","timestamp":1722618742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644624001909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":103,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S1359644624001909"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104065","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled heparin: Past, present, and future","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2024.104065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104065"}}